More than a 100-year experience with drug development and discovery
More than 700 scientists and specialists work within research and development in LEO Pharma to develop new treatments. Together, we take the drugs all the way - from research to registration.
Research and Development
We have more than a 100-year of experience with drug development and discovery
Error while rendering view [MediaElementOverlay]. The rendering is lacking some configuration. Please, read description below and try to fix the problem.
- Missing DataSource.
LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma
Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 M EUR has been completed.
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825
BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.